Tirzepatide 20mg

About Tirzepatide

What is Tirzepatide?

Tirzepatide (CAS 2023788-19-2) is a synthetic 39-amino-acid peptide built as a dual agonist of two metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). A C20 fatty diacid is attached to the peptide backbone so the molecule stays in circulation longer. That design is why published research protocols often use a weekly schedule.

Werhner Lab supplies tirzepatide as lyophilised powder in 10 mg and 20 mg vials.

CAS: 2023788-19-2. Molecular weight: ~4813.5 g/mol. Receptor profile: GIP-R and GLP-1R together.

How Tirzepatide is studied in the literature

Published peptide research describes tirzepatide mainly through dual-receptor pharmacology and metabolic models. The notes below are scientific background from that literature. They are not claims about what Werhner Lab material will do in any person.

Body composition and energy-balance research

In preclinical and in-vitro metabolic models, tirzepatide is used to study body composition, adiposity, and energy-balance pathways. Researchers compare dual GIP/GLP-1 activation with GLP-1-only agonists.

Glucose-regulation pathways

It is also used in models of glucose control and incretin signalling, including dose-dependent receptor pharmacology at GIP-R and GLP-1R.

Within the incretin class — how Tirzepatide differs

Feature	Semaglutide	Tirzepatide	Retatrutide
Receptor activation	GLP-1R only	GIP-R + GLP-1R (dual)	GIP-R + GLP-1R + GCG-R (triple)
Amino acids	31	39	39
Distinct mechanism	Long-acting GLP-1 analogue	Dual incretin; GIP-biased profile in many papers	Adds glucagon-receptor activity

The GIP arm is the difference versus semaglutide. Tirzepatide does not activate the glucagon receptor; that is the step up to retatrutide.

Research areas

• GIP and GLP-1 receptor binding and signalling assays
• Preclinical metabolic models of glucose handling and body composition
• Head-to-head work versus single-receptor GLP-1 analogues
• Formulation and stability of long-acting acylated peptides

Specifications

CAS	2023788-19-2
Molecular weight	~4813.5 g/mol
Receptor profile	Dual agonist: GIP-R / GLP-1R
Purity	≥ 97.5% (supplier batch spec; CoA per lot)
Form	Lyophilised powder in a sealed glass vial
Sizes	10 mg, 20 mg

Storage

Lyophilised powder: −20°C for long-term storage. 2–8°C for short-term use before reconstitution.

Reconstituted: 2–8°C; use within the window stated on the CoA / lab SOP. Do not freeze after reconstitution unless your protocol says otherwise.

Quality

• Each batch ships to a stated purity specification
• Identity and purity are documented on the lot CoA
• Quote the batch number (e.g. TZ10-8492 / TZ20-3105) when you request documents

Important notice — Research Use Only

Tirzepatide is supplied by Werhner Lab strictly as a laboratory research compound. The research context above comes from published scientific literature and is background only. It is not a medical claim and does not describe what this material will do in any individual. This product is not a medicine, dietary supplement, or cosmetic, and it is not offered for over-the-counter human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. Laboratory research only. Not for human consumption.